Delving into the Latest Updates on PP-1002 with Synapse

Overview

Basic Info

Drug Type

Bacteriophage therapy

Synonyms

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Complicated urinary tract infectionEscherichia Coli Infections

Originator Organization-

Active Organization-

Inactive Organization

BioAster

Pherecydes Pharma SA

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

The expression of the cDNA for alcohol-inducible rabbit liver microsomal cytochrome P-450 form 3a (P450IIE1) in Saccharomyces cerevisiae, with the use of the copper-inducible yeast metallothionein (CUP1) promoter and the ADH1 promoter, is described. Strains 50.L4 and PP1002 were compared for optimal levels of expressed protein. Immunoblot analysis showed that a much higher level of expression of cytochrome P-450 3a is obtained with strain 50.L4, and that the uninduced levels of expressed protein are similar with the two promoters. With the CUP1 promoter, transcription of the cDNA is strongly induced in the presence of cupric ions, and the amount of immunoreactive protein expressed in increased 20-fold in strain 50.L4, such that it constitutes 0.8% of the total cellular protein. The cytochrome P-450 holoenzyme content of these cells, calculated from the reduced CO difference spectrum, is about 0.02 nmole/mg of protein, or 0.1% of the total cellular protein. The holoenzyme content of microsomes prepared from these cells is up to 0.06 nmole/mg of protein, or 0.4% of the microsomal protein. Microsomal assays for ethylene formation from N-nitrosodiethylamine and for aniline p-hydroxylation, two reactions typical of purified rabbit cytochrome P-450 form 3a, showed that the cytochrome synthesized in yeast catalyzes both reactions. Furthermore, polyclonal anti-3a IgG completely inhibits the reactions with both substrates in yeast microsomes. A comparison of the product ratios from these substrates showed that the cytochrome P-450 3a expressed in yeast has catalytic activities similar to those of the authentic rabbit protein.

100 Deals associated with PP-1002

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Complicated urinary tract infection	Preclinical	FR	BioAster	12 Jul 2021
Complicated urinary tract infection	Preclinical	FR	Pherecydes Pharma SA	12 Jul 2021
Escherichia Coli Infections	Preclinical	FR	BioAster	12 Jul 2021
Escherichia Coli Infections	Preclinical	FR	Pherecydes Pharma SA	12 Jul 2021